Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribaxamase for C. diff Prevention in LRTI
NCT02563106Phase 2Completed
- Sponsor
- Theriva Biologics
- Start
- Oct 2015
- Primary completion
- Nov 2016
- Modality
- Replacement Enzymes
- Countries
- 7
01
Overview
A Phase 2 trial of ribaxamase in Clostridioides difficile infection (CDI), sponsored by Theriva Biologics. Started Oct 2015; status: completed.
02
Drugs
ribaxamase
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02563106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563106.